Arecor Therapeutics PLC Arecor granted key patents in Europe and China (9686D)
27 June 2023 - 4:00PM
UK Regulatory
TIDMAREC
RNS Number : 9686D
Arecor Therapeutics PLC
27 June 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT
PROPRIETARY INSULIN PRODUCTS
Patents further strengthen Group's extensive patent portfolio
protecting its Arestat(TM) technology and innovative insulin
products, AT278 and AT247
Cambridge, UK, 27 June 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the European
Patent Office has granted a key patent ( EP3518892), protecting
novel formulations of the Group's proprietary insulin products,
AT278 and AT247. In addition, the China National Intellectual
Property Administration has granted a further patent (CN110582285)
protecting AT278 and AT247.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"Our innovative Arestat(TM) enabled insulin products, AT278 and
AT247, have the potential to address key needs in the better
treatment of diabetes. AT278 is a 'disrupter insulin', a unique
formulation which combines an ultra-rapid profile and high
concentration and has potential as the gold standard insulin for
the growing population of people with high daily insulin needs, as
well as a key enabler for pump miniaturisation and extended
wear-time. AT247 has a 'best-in-class' ultra-rapid pharmacokinetic
profile with the potential to enable fully automated insulin
delivery systems. Diabetes is one of the leading causes of death
and disability worldwide, and affects people regardless of country,
age group, or sex. These additional granted patents aim to serve
and protect Arecor's innovative technologies in these important
markets."
Arecor has invested in a strong patent portfolio to protect the
Arestat(TM) technology platform and its proprietary pipeline
products. The Group's intellectual property (IP) portfolio
currently comprises 36 patent families, including >75 granted
patents in Europe, the US and in other key territories, and
provides protection for its key products. As part of this strategy,
Arecor has robust IP that protects the novel compositions of AT278
and AT247 as well as their specific properties and methods of use
until 2037.
AT278 is an ultra-concentrated (500 U/mL) novel formulation of
insulin that has been designed to accelerate the absorption of
insulin post injection, even when delivered at a high
concentration. It has the potential to enable more effective
management of blood glucose levels, especially in people with high
daily insulin needs, whilst maintaining the convenience and
compliance benefits that come from a lower injection volume via a
single injection. Moreover, a truly rapid acting concentrated
insulin is also a critical step towards developing the next
generation of miniaturised insulin patch pumps, as well as pumps
with longer wear-time and that can serve people with diabetes with
a broader range of daily insulin needs.
AT247 is an ultra-rapid insulin that has been demonstrated in
Phase I clinical studies to significantly accelerate insulin
absorption. The faster absorption enables a more effective
management of blood glucose levels for people living with diabetes,
allowing for dosing closer to mealtimes. Faster acting insulins, in
combination with state-of-the-art insulin pumps, glucose sensors
and treatment algorithms are all necessary components of an
'artificial pancreas' designed to more closely mimic natural
insulin function.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDBGDLBGDDGXL
(END) Dow Jones Newswires
June 27, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024
